Catequentinib
Maintenance Treatment
Taizhou HospitalSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Maintenance Treatment cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Toripalimab Taizhou Hospital | Phase 3 | B |
Venetoclax Henan Cancer Hospital | N/A | D |
INTERFERON ALPHA 1B Henan Cancer Hospital | N/A | D |
Azacitidine Henan Cancer Hospital | N/A | D |
Thalidomide Henan Cancer Hospital | N/A | D |
Same molecule, other indications
Catequentinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →